清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

福尔菲里 医学 阿柏西普 贝伐单抗 伊立替康 奥沙利铂 内科学 养生 氟尿嘧啶 结直肠癌 肿瘤科 安慰剂 胃肠病学 外科 化疗 癌症 病理 替代医学
作者
Eric Van Cutsem,Josep Tabernero,Radek Lakomý,Hans Prenen,Jana Prausová,Teresa Macarulla,Paul Ruff,Guy A. Van Hazel,Vladimir Moiseyenko,David Ferry,Joe McKendrick,Jonathan Polikoff,Alexia Tellier,R Castan,Carmen J. Allegra
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:30 (28): 3499-3506 被引量:1286
标识
DOI:10.1200/jco.2012.42.8201
摘要

Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab. Patients and Methods Patients were randomly assigned to receive aflibercept (4 mg/kg intravenously; 612 patients) or placebo (614 patients) every 2 weeks in combination with FOLFIRI. Treatment was administered until disease progression or unacceptable toxicity. The primary end point was overall survival. Results Adding aflibercept to FOLFIRI significantly improved overall survival relative to placebo plus FOLFIRI (hazard ratio [HR], 0.817; 95.34% CI, 0.713 to 0.937; P = .0032) with median survival times of 13.50 versus 12.06 months, respectively. Aflibercept also significantly improved progression-free survival (PFS; HR, 0.758; 95% CI, 0.661 to 0.869; P < .0001), with median PFS times of 6.90 versus 4.67 months, respectively. The effects on overall survival and PFS exhibited a consistent trend across prespecified subgroup analyses, including bevacizumab pretreated patients. Response rate was 19.8% (95% CI, 16.4% to 23.2%) with aflibercept plus FOLFIRI compared with 11.1% (95% CI, 8.5% to 13.8%) with placebo plus FOLFIRI (P = .0001). Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti–vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities. Conclusion Aflibercept in combination with FOLFIRI conferred a statistically significant survival benefit over FOLFIRI combined with placebo in patients with mCRC previously treated with oxaliplatin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
meijuan1210完成签到 ,获得积分10
7秒前
Johnson完成签到 ,获得积分10
11秒前
无悔完成签到 ,获得积分10
1分钟前
al完成签到 ,获得积分10
1分钟前
希勤发布了新的文献求助10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
轩羊羊完成签到 ,获得积分10
2分钟前
zyjsunye完成签到 ,获得积分0
2分钟前
龙猫爱看书完成签到,获得积分10
2分钟前
自由飞翔完成签到 ,获得积分10
3分钟前
小苹果完成签到,获得积分10
3分钟前
orixero应助常证明采纳,获得10
3分钟前
creep2020完成签到,获得积分10
3分钟前
3分钟前
常证明发布了新的文献求助10
4分钟前
汎影完成签到,获得积分10
4分钟前
研友_Z7XY28完成签到 ,获得积分10
4分钟前
小强完成签到 ,获得积分10
4分钟前
简单幸福完成签到 ,获得积分10
5分钟前
zhangguo完成签到 ,获得积分10
5分钟前
常证明完成签到,获得积分20
5分钟前
6分钟前
小巫发布了新的文献求助10
6分钟前
小巫完成签到,获得积分10
6分钟前
wx1完成签到 ,获得积分0
6分钟前
Jasper应助常证明采纳,获得10
6分钟前
aniu完成签到,获得积分10
7分钟前
energyharvester完成签到 ,获得积分10
7分钟前
7分钟前
常证明发布了新的文献求助10
7分钟前
lovelife完成签到,获得积分10
7分钟前
黄腾完成签到,获得积分10
8分钟前
xiaolang2004完成签到,获得积分10
9分钟前
emchavezangel完成签到,获得积分10
9分钟前
修仙应助emchavezangel采纳,获得10
9分钟前
英喆完成签到 ,获得积分10
9分钟前
Chang完成签到 ,获得积分10
9分钟前
爆米花应助希勤采纳,获得10
12分钟前
12分钟前
李伟发布了新的文献求助10
12分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
XAFS for Everyone (2nd Edition) 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3134020
求助须知:如何正确求助?哪些是违规求助? 2784845
关于积分的说明 7768807
捐赠科研通 2440219
什么是DOI,文献DOI怎么找? 1297340
科研通“疑难数据库(出版商)”最低求助积分说明 624925
版权声明 600792